Cargando…

Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation

OBJECTIVES: The purpose of the study was to assess the validity of the hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) and of pulmonary comorbidity prior to HCT in terms of predicting non‐relapse mortality (NRM) and overall survival (OS). METHODS: In this retrospective single‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Schierbeck, Frederikke, Mortensen, Jann, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, Sengeløv, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092052/
https://www.ncbi.nlm.nih.gov/pubmed/36153797
http://dx.doi.org/10.1111/ejh.13869
_version_ 1785023257308561408
author Schierbeck, Frederikke
Mortensen, Jann
Andersen, Niels S.
Friis, Lone S.
Kornblit, Brian
Petersen, Søren L.
Schjødt, Ida
Sengeløv, Henrik
author_facet Schierbeck, Frederikke
Mortensen, Jann
Andersen, Niels S.
Friis, Lone S.
Kornblit, Brian
Petersen, Søren L.
Schjødt, Ida
Sengeløv, Henrik
author_sort Schierbeck, Frederikke
collection PubMed
description OBJECTIVES: The purpose of the study was to assess the validity of the hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) and of pulmonary comorbidity prior to HCT in terms of predicting non‐relapse mortality (NRM) and overall survival (OS). METHODS: In this retrospective single‐center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low‐risk, intermediate‐risk, and high‐risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT‐CI. RESULTS: In univariate analysis, the HCT‐CI and the PCS were associated with OS after transplantation when comparing patients in high‐risk groups with patients in low‐risk groups. Using the PCS, the hazard ratios (HRs) of the 2‐year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p < .001) and 3.27 (p < .001), respectively, whereas the HRs using the HCT‐CI were 1.83 (p < .001) and 2.57 (p = .002). The 2‐year NRM incidence in the three risk‐groups in the entire population was significant using both indexes. In the MAC group, the 2‐year NRM was significant using the PCS (p = .003), but not using the HCT‐CI (p = .23). CONCLUSIONS: Our study suggest that pulmonary function alone is a strong predictor of 2‐year OS and NRM after HCT.
format Online
Article
Text
id pubmed-10092052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100920522023-04-13 Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation Schierbeck, Frederikke Mortensen, Jann Andersen, Niels S. Friis, Lone S. Kornblit, Brian Petersen, Søren L. Schjødt, Ida Sengeløv, Henrik Eur J Haematol Original Articles OBJECTIVES: The purpose of the study was to assess the validity of the hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI) and of pulmonary comorbidity prior to HCT in terms of predicting non‐relapse mortality (NRM) and overall survival (OS). METHODS: In this retrospective single‐center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low‐risk, intermediate‐risk, and high‐risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT‐CI. RESULTS: In univariate analysis, the HCT‐CI and the PCS were associated with OS after transplantation when comparing patients in high‐risk groups with patients in low‐risk groups. Using the PCS, the hazard ratios (HRs) of the 2‐year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p < .001) and 3.27 (p < .001), respectively, whereas the HRs using the HCT‐CI were 1.83 (p < .001) and 2.57 (p = .002). The 2‐year NRM incidence in the three risk‐groups in the entire population was significant using both indexes. In the MAC group, the 2‐year NRM was significant using the PCS (p = .003), but not using the HCT‐CI (p = .23). CONCLUSIONS: Our study suggest that pulmonary function alone is a strong predictor of 2‐year OS and NRM after HCT. John Wiley and Sons Inc. 2022-10-21 2023-01 /pmc/articles/PMC10092052/ /pubmed/36153797 http://dx.doi.org/10.1111/ejh.13869 Text en © 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Schierbeck, Frederikke
Mortensen, Jann
Andersen, Niels S.
Friis, Lone S.
Kornblit, Brian
Petersen, Søren L.
Schjødt, Ida
Sengeløv, Henrik
Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
title Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
title_full Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
title_fullStr Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
title_full_unstemmed Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
title_short Pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
title_sort pulmonary function is a strong predictor of 2‐year overall survival and non‐relapse mortality after allogenic hematopoietic cell transplantation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092052/
https://www.ncbi.nlm.nih.gov/pubmed/36153797
http://dx.doi.org/10.1111/ejh.13869
work_keys_str_mv AT schierbeckfrederikke pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation
AT mortensenjann pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation
AT andersennielss pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation
AT friislones pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation
AT kornblitbrian pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation
AT petersensørenl pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation
AT schjødtida pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation
AT sengeløvhenrik pulmonaryfunctionisastrongpredictorof2yearoverallsurvivalandnonrelapsemortalityafterallogenichematopoieticcelltransplantation